C 型肝炎治療ガイドライン （第 4版） - jsh.or.jp

1 C 4 2015 9 ** * * ** Corresponding author: 173-8605 2 11 1 Tel 03(3964)1211 Fax 03(3964)6627 Email 2012 5 1 2013 8 ALT U/l +Peg-IFN -2b+ 3 1 Peg-IFN (IFN)

2 2013 11 2 +Peg-IFN + 3 IFN B 2014 9 3 C C SVR C COI 4 HCV 2014 10 2 2014 12 +Peg-IFN -2b+ 3 HCV 2015 3 HCV 2015 5 2 DAA DAA 2015 8 2 2015 9 4 1

3 IFN / C 1-1 C 1 1-2 C 1 1-3 C 2 1-4 C 3 1-5 SVR 4 IFN 5 2-1 IFN 5 2-2 PEG IFN 5 2-3 IFN 6 2-4 IFN 6 2-5 6 2-6 Peg-IFN -2a Peg-IFN -2b 7 2-7 IFN 8 2-8 IFN 10 2-9 IFN

4 10 . 11 3-1 11 3-2 11 Direct Acting Antivirals (DAAs) 13 4-1 13 4-1 -1 14 4-1 -1 -1 14 4-1-1-2 15 4-1-1-3 2 16 4-1 -2 17 4-1 -3 18 4-1 -4

5 19 4-2 20 4-2 -1 20 4-2-1-1 21 4-2-1-2 23 4-2-1-3 24 4-2 -2 25 4-2 -3 25 4-2 -4 26 4-3 26 4-3-1 26 4-3-2 27 4-3-3 / 27 4-3-3-1 27 4-3-3-2 28 4-3-3-2-1 IFN 28 4-3-3-2-2 30 4-3-3-3

6 32 4-3-3-4 33 4-3-3-5 33 4-4 37 4-4 -1 37 4-4-1-1 37 4-4-1-2 39 4-4-1-3 39 4-4-2 39 4-4 -3 39 4-4-4 40 4-5 40 4-5-1 41 4-5-1-1 41 4-5-1-2 41 4-5-2 43 4-5 -3 45 4-5 -4

7 46 4-5-5 46 4-6 / 46 4-6-1 47 4-6-2 48 4-6 -3 49 4-6 -4 50 4-6-5 51 52 5-1 1 48 5-1- 1 48 5-1-1-1 IFN-based antiviral therapy 52 5-1-1-2 IFN-free antiviral therapy 52 5-1-2 54 5-1-3 55 5-1-4 56 5-1-4-1.

8 DAA 54 5-1-4-1-1. 57 5-1-4-1-2 IFN(+ ) 57 5-1-4-2. DAA 58 5-1-4-2-1. DAA IFN 58 5-1-4-2-2. DAA IFN 60 5-2 61 5-2-1 61 5-2-2 62 5-3 ALT 63 64 6-1 64 6-1- 1 Peg-IFN+ 65 6-1-2 /

9 65 6-1 -3 / 66 6-1-4 / 67 6-1-5 1 67 6-1-6 68 6-2 69 6-3 70 71 7-1 UDCA 71 7-2 SNMC 71